Longitudinal monocyte Human leukocyte antigen-DR expression is a prognostic marker in critically ill patients with decompensated liver cirrhosis

Liver International

Volumn 29, Issue 4, 2009, Pages 536-543

  Berres, Marie Luise ^a   Schnyder, Barbara ^a   Yagmur, Eray ^a   Inglis, Brett ^a   Stanzel, Sven ^a   Tischendorf, Jens J W ^a   Koch, Alexander ^a   Winograd, Ron ^a   Trautwein, Christian ^a   Wasmuth, Hermann E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Cirrhosis; Critical illness; HLA DR; Immune paralysis

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; CYTOKINE RELEASE; DECOMPENSATED LIVER CIRRHOSIS; FEMALE; HUMAN; INTENSIVE CARE; MALE; MONOCYTE; MORTALITY; MULTIPLE ORGAN FAILURE; PROGNOSIS; PROTEIN EXPRESSION; SEPSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CRITICAL ILLNESS; FEMALE; HLA-DR ANTIGENS; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-6; LIVER CIRRHOSIS; LIVER FAILURE; MALE; MIDDLE AGED; MONOCYTES; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 62749198150     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01870.x     Document Type: Article

References (31)

1. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-54.
2. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: Report on the 7th meeting of the International Ascites Club. Gut 2005; 54: 718-25.
3. Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005; 42: 195-201.
4. Lin CY, Tsai IF, Ho YP, et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007; 46: 816-26.
5. Xing T, Li L, Cao H, Huang J. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol 2007; 147: 184-8.
6. Antoniades CG, Berry PA, Davies ET, et al. Reduced monocyte HLA-DR expression: A novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. Hepatology 2006; 44: 34-43.
7. Becker S. Interferon-gamma accelerates immune proliferation via its effect on monocyte HLA-DR expression. Cell Immunol 1985; 91: 301-7.
8. Murray HW. Current and future clinical applications of interferon-gamma in host antimicrobial defense. Intensive Care Med 1996; 22(Suppl. 4): S456-61.
9. Oczenski W, Krenn H, Jilch R, et al. HLA-DR as a marker for increased risk for systemic inflammation and septic complications after cardiac surgery. Intensive Care Med 2003; 29: 1253-7.
10. Ho YP, Sheen IS, Chiu CT, Wu CS, Lin CY. A strong association between down-regulation of HLA-DR expression and the late mortality in patients with severe acute pancreatitis. Am J Gastroenterol 2006; 101: 1117-24.
11. Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schuttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med 2002; 30: 1015-23.
12. Perry SE, Mostafa SM, Wenstone R, Shenkin A, Mclaughlin PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med 2003; 29: 1245-52.
13. Antoniades CG, Wendon J, Vergani D. Paralysed monocytes in acute on chronic liver disease. J Hepatol 2005; 42: 163-5.
14. Cholongitas E, Senzolo M, Patch D, Shaw S, Hui C, Burroughs AK. Review article: Scoring systems for assessing prognosis in critically ill adult cirrhotics. Aliment Pharmacol Ther 2006; 24: 453-64.
15. Wasmuth HE, Kunz D, Graf J, et al. Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-alpha. Crit Care Med 2004; 32: 1109-14.
16. Turina M, Dickinson A, Gardner S, Polk HC Jr. Monocyte HLA-DR and interferon-gamma treatment in severely injured patients - a critical reappraisal more than a decade later. J Am Coll Surg 2006; 203: 73-81.
17. Rabe C, Schmitz V, Paashaus M, et al. Does intubation really equal death in cirrhotic patients? Factors influencing outcome in patients with liver cirrhosis requiring mechanical ventilation. Intensive Care Med 2004; 30: 1564-71.
18. Arabi Y, Ahmed QA, Haddad S, Aljumah A, Al-Shimemeri A. Outcome predictors of cirrhosis patients admitted to the intensive care unit. Eur J Gastroenterol Hepatol 2004; 16: 333-9.
19. Shellman RG, Fulkerson WJ, Delong E, Piantadosi CA. Prognosis of patients with cirrhosis and chronic liver disease admitted to the medical intensive care unit. Crit Care Med 1988; 16: 671-8.
20. Aggarwal A, Ong JP, Younossi ZM, Nelson DR, Hoffman-Hogg L, Arroliga AC. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001; 119: 1489-97.
21. Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology 2001; 34: 255-61.
22. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-77.
23. Koppelman B, Neefjes JJ, De Vries JE, De Waal Malefyt R. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997; 7: 861-71.
24. Morel AS, Coulton G, Londei M. Regulation of major histocompatibility complex class II synthesis by interleukin-10. Immunology 2002; 106: 229-36.
25. Nagaki M, Iwai H, Naiki T, Ohnishi H, Muto Y, Moriwaki H. High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis. J Infect Dis 2000; 182: 1103-8.
26. Yumoto E, Higashi T, Nouso K, et al. Serum gamma-interferon-inducing factor (IL-18) and IL-10 levels in patients with acute hepatitis and fulminant hepatic failure. J Gastroenterol Hepatol 2002; 17: 285-94.
27. Wolk K, Docke WD, Von Baehr V, Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000; 96: 218-23.
28. Wolk K, Kunz S, Crompton NE, Volk HD, Sabat R. Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance. J Biol Chem 2003; 278: 18030-6.
29. Schlichting P, Christensen E, Fauerholdt L, Poulsen H, Juhl E, Tygstrup N. Main causes of death in cirrhosis. Scand J Gastroenterol 1983; 18: 881-8.
30. Nierhaus A, Montag B, Timmler N, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003; 29: 646-51.
31. Fiuza C, Salcedo M, Clemente G, Tellado JM. Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease. Clin Diagn Lab Immunol 2002; 9: 433-9.